|
自体CIK细胞免疫疗法治疗中晚期非小细胞肺癌的临床研究 |
|
自体CIK细胞免疫疗法治疗中晚期非小细胞肺癌的临床研究 |
|
|
【摘要】 目的 观察自体CIK细胞过继性免疫疗法对中晚期非小细胞肺癌患者的临床疗效。 方法 体外利用抗CD3单抗、IL2、IFNγ等细胞因子从患者外周血单个核细胞(PBMC)中诱导扩增CIK细胞,培养11~14 d后,分3个疗程回输患者体内,观察患者临床症状改善及生活质量改善状况,并用流式细胞仪检测回输前后患者T细胞亚群和NK细胞变化。 结果 86例接受自体CIK细胞治疗患者中,PR+MR为72例,总缓解率为83.72%。治疗前、后肿瘤患者临床症状有明显改善,有显著性差异(P<0.01)。CIK细胞经培养后细胞总数和CD3、CD56 T效应细胞均获得大量增殖,自体回输免疫治疗后,CD3、CD4 T细胞和NK细胞比例均显著提高(P<0.01)。 结论 从中晚期非小细胞肺癌患者外周血PBMC中可高效扩增CIK细胞,自体回输能显著提高患者免疫功能,改善临床症状,提高生存质量,延长患者生存期。
【关键词】 CIK细胞; 过继免疫治疗; 非小细胞肺癌
【Abstract】 Objective To observe the therapy effect of cytokineinduced killer (CIK) in PBMC of patients with advanced nonsmallcell lung cancer. Methods CIK cells were induced and amplified from PBMC of 68 NSCLC patients by in vitro incubation with IL2,IFNγ,antiCD3 monoclonal antibody for 1114 days and then transfused back to patients. The changes of T cell and NK cell of patients before and after CIK cell treatment with FCM were tested. Results After 1114 days culture, the total number of CIK cells and CD3+,CD56+ T cells expanded greatly. After being treated with CIK cells, the numbers of CD3,CD4 T cell and NK cells of patients increased significantly (P<0.01). The clinical symptoms of 86 patients were improved clearly. Conclusion CIK cells may be expanded effectively from patients with advanced NSCLC. The adoptive immunotherapy of autoimmunity of CIK cells can significantly enhance cellular immune function and improve the clinical symptom of patients.
【Key words】 cytokineinduced killer cells; adoptive immunotherapy; nonsmallcell lung cancer
CIK细胞(cytokineinduced killer cell)是目前所知杀伤活性较强的肿瘤生物治疗效应细胞,其主要表达T细胞标记的CD3细胞和表达NK标记的CD56细胞。正常情况下,人体CD3、CD56表型的细胞仅占外周血细胞的1%~5%,肿瘤患者其T细胞功能则更低。自体CIK细胞免疫疗法就是从人体外周血中分离CD3、CD56以及CD4、CD8等细胞,在体外大量扩增后再回输到体内,以迅速提高机体T细胞免疫功能[1]。国内外已有研究表明,大量输注CIK细胞的作用能提高乳腺癌等恶性肿瘤患者自身免疫细胞功能,清除手术、放、 [1] [2] [3] [4] 下一页 |
|
|
|
上一个论文: 现阶段我国保险企业的创新策略 下一个论文: 心胸比对左心瓣膜返流患者左心室扩大预示价值的临床研究 |
|